Diversification of Funding Through Stock Market and Bank Financing
First written in FY2017. 26 of 33 entries say "Advanced", first in FY2018-Q1. Latest entry: FY2026.
12 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In November 2025, during the consolidated fiscal year, the Company secured ¥14.2 billion in growth funding, net of expenses, through an overseas offering of new shares. The funds are scheduled to be used to advance the SB623 chronic traumatic brain injury program in the United States and the SB623 chronic cerebral infarction program in Japan.」
The Company secured ¥14.2 billion in net proceeds through an overseas offering of new shares, and plans to use the growth funding for clinical trials for traumatic brain injury in the United States and cerebral infarction in Japan have taken concrete shape. - FY2026-H1AdvancedAnnual report
「Funds provided by financing activities during the six-month consolidated accounting period amounted to ¥1,895 million, compared with ¥340 million in proceeds during the same period of the previous year. This primarily reflected ¥134 million in payments for the repayment of long-term borrowings, ¥1,080 million in proceeds from the issuance of convertible bonds with stock acquisition rights, and ¥975 million in proceeds from the issuance of shares.」
In addition to entering into a commitment line agreement with a bank, the Company raised ¥1,080 million through convertible bonds with stock acquisition rights and ¥975 million through the issuance of shares, indicating progress in executing its fundraising plans. - FY2025AdvancedAnnual report
「The Company entered into the following commitment line agreement with Resona Bank, Ltd. to fund the establishment of its manufacturing, logistics and sales systems following approval of a partial change to the marketing authorization for Acurago®. ② Facility amount: ¥1 billion ③ Agreement date: March 2025 ④ Facility expiry: March 2027」
The Company entered into a ¥1 billion commitment line agreement with Resona Bank through March 2027 to fund the establishment of systems following approval of a partial change to Acurago®'s marketing authorization. In addition, ¥2.08 billion was raised through a third-party allotment of new shares and convertible bonds with stock acquisition rights. - FY2025-Q1RestatedAnnual report
「During the first quarter, the stock acquisition rights related to the relevant bonds with stock acquisition rights subject to an exercise price adjustment clause were exercised as follows. / Number of the relevant bonds with stock acquisition rights subject to an exercise price adjustment clause exercised during the quarter (units): 7,000 / Number of shares delivered upon exercise during the quarter (shares): 700,000 / Funds raised through exercises during the quarter (¥ thousands): 485,800 / Cumulative number of the relevant bonds with stock acquisition rights subject to an exercise price adjustment clause exercised as of the end of the quarter (units): 90,000 / Cumulative number of shares delivered in connection with the relevant bonds with stock acquisition rights subject to an exercise price adjustment clause as of the end of the quarter (shares): 9,000,000 / Cumulative funds raised in connection with the relevant bonds with stock acquisition rights subject to an exercise price adjustment clause as of the end of the quarter (¥ thousands): 6,389,200」
With respect to the 34th Series Stock Acquisition Rights, 700,000 shares were delivered and ¥485 million was raised during the quarter. Cumulatively, 9,000,000 shares had been delivered and ¥6,389 million had been raised, confirming the status again. - FY2024AdvancedAnnual report
「All exercises of the 34th Series Stock Acquisition Rights issued by the Company had been completed as of 26 February 2024. A total of 9,000,000 new shares were issued and ¥6,436 million was raised.」
The exercise of the 34th Series Stock Acquisition Rights was completed on 26 February 2024. A total of 9 million shares were issued and ¥6,436 million was raised. Capital-market fundraising progressed from the planning stage to completion. - FY2024-Q3AdvancedAnnual report
「Number of the relevant bonds with stock acquisition rights subject to an exercise price adjustment clause exercised during the quarter (units): 5,500 / Number of shares delivered upon exercise during the quarter (shares): 550,000 / Funds raised through exercises during the quarter (¥ thousands): 381,700 / Cumulative number of the relevant bonds with stock acquisition rights subject to an exercise price adjustment clause exercised as of the end of the quarter (units): 59,000 / Cumulative number of shares delivered in connection with the relevant bonds with stock acquisition rights subject to an exercise price adjustment clause as of the end of the quarter (shares): 5,900,000 / Cumulative funds raised in connection with the relevant bonds with stock acquisition rights subject to an exercise price adjustment clause as of the end of the quarter (¥ thousands): 4,237,800」
With respect to the 34th Series Stock Acquisition Rights, 550,000 shares were delivered and ¥381.7 million was raised during the quarter. Cumulatively, 5,900,000 shares had been delivered and ¥4,237.8 million had been raised, indicating further progress in raising funds from the capital markets. - FY2024-Q2AdvancedAnnual report
「Number of the relevant bonds with stock acquisition rights subject to an exercise price adjustment clause exercised during the quarter (units): 1,100 / Number of shares delivered upon exercise during the quarter (shares): 110,000 / Funds raised through exercises during the quarter (¥ thousands): 76,340 / Cumulative number of the relevant bonds with stock acquisition rights subject to an exercise price adjustment clause exercised as of the end of the quarter (units): 53,500 / Cumulative number of shares delivered in connection with the relevant bonds with stock acquisition rights subject to an exercise price adjustment clause as of the end of the quarter (shares): 5,350,000 / Cumulative funds raised in connection with the relevant bonds with stock acquisition rights subject to an exercise price adjustment clause as of the end of the quarter (¥ thousands): 3,856,100」
With respect to the 34th Series Stock Acquisition Rights, 1,100 units were exercised during the quarter, 110,000 shares were delivered and ¥76.34 million was raised. Cumulatively, 5,350,000 shares had been delivered and ¥3,856.1 million had been raised, indicating further progress in raising funds from the capital markets. - FY2024-Q1AdvancedAnnual report
「Number of the relevant bonds with stock acquisition rights subject to an exercise price adjustment clause exercised during the quarter (units): 7,700 / Number of shares delivered upon exercise during the quarter (shares): 770,000 / Funds raised through exercises during the quarter (¥ thousands): 535,380」
With respect to the 34th Series Stock Acquisition Rights, 7,700 units were exercised during the quarter, 770,000 shares were delivered and ¥535.38 million was raised. Cumulatively, 5,240,000 shares had been delivered and ¥3,779.76 million had been raised. - FY2023AdvancedAnnual report
「In addition, the issuance of the 32nd Series Stock Acquisition Rights with an exercise price adjustment clause, exercise designation and suspension designation clauses, and the 34th Series Stock Acquisition Rights with exercise designation and suspension designation clauses, together with repayments of bank borrowings and other items, resulted in ¥9,445 million in cash provided by financing activities.」
The 32nd Series Stock Acquisition Rights had been fully completed up to the delivery of 7,500,000 shares and the raising of approximately ¥7,698.1 million, while the 34th Series Stock Acquisition Rights had progressed to the delivery of 4,470,000 shares and the raising of approximately ¥3,244.38 million. - FY2023-Q3AdvancedAnnual report
「1) Establishment of post-launch manufacturing capacity and inventory for the SB623 chronic-stage traumatic brain injury program: ¥6,846 million, November 2022 to November 2024 / 2) Establishment of a post-launch commercialization system and promotion expenses for the SB623 chronic-stage traumatic brain injury program: ¥2,110 million, November 2022 to November 2024 / Total: ¥8,956 million」
A plan was disclosed to issue the 34th Series of Stock Acquisition Rights and use estimated net proceeds of ¥8,956.7 million to fund the establishment of manufacturing capacity and inventory and a commercialization system from November 2022 through November 2024. - FY2023-Q2AdvancedAnnual report
「During the second quarter, the stock acquisition rights attached to convertible bonds with an exercise-price adjustment clause and other instruments were exercised as follows. Number exercised during the quarter (units): 47,000. Number of shares delivered upon exercise during the quarter (shares): 4,700,000. Funds raised through exercises during the quarter (¥ thousands): 4,457,050」
During the quarter, 47,000 of the 32nd Series of Stock Acquisition Rights were exercised, 4.7 million shares were delivered and ¥4,457.05 million was raised. Cumulatively, 75,000 rights have been exercised, 7.5 million shares delivered and ¥7,698.1 million raised, indicating further progress in funding from the capital markets. - FY2023-Q1AdvancedAnnual report
「Number of such convertible bonds with stock acquisition rights and other instruments with an exercise-price adjustment clause exercised during the quarter (units): 28,000 Number of shares delivered upon exercise during the quarter (shares): 2,800,000 Funds raised through exercises during the quarter (¥ thousands): 3,241,050」
During the quarter, 28,000 of the 32nd Series of Stock Acquisition Rights were exercised, 2.8 million shares were delivered and ¥3,241 million was raised. Funding from the capital markets is progressing through the execution stage. - FY2022AdvancedAnnual report
「Funding amount (estimated net proceeds): ¥12,386,000,000」
A plan was disclosed to raise estimated net proceeds of ¥12,386 million through the 32nd Series of Stock Acquisition Rights for expenditures from March 2022 through March 2025. The funds will be used for post-launch manufacturing and inventory for SB623's chronic-stage traumatic brain injury program, establishing a commercialization system, and clinical development of the cerebral infarction program. - FY2022-Q3AdvancedAnnual report
「The company entered into the commitment line agreement below with Resona Bank to fund the establishment of post-launch manufacturing, logistics and sales systems for SB623. 1. Borrowing limit: ¥1,000 million 2. Agreement date: 15 December 2021 3. Commitment period: 14 January 2022 to 30 June 2023」
The company entered into a commitment line agreement with Resona Bank, with a borrowing limit of ¥1 billion and a commitment period from 14 January 2022 to 30 June 2023, to establish post-launch manufacturing, logistics and sales systems for SB623. - FY2022-Q2Increase in borrowings outstandingAnnual report
「Total lending commitment agreements ¥7,600 million Amount drawn ¥3,025 million Undrawn amount ¥4,575 million」
The total lending commitments remained unchanged at ¥7.6 billion, while the amount drawn increased from ¥2.8 billion to ¥3,025 million and the undrawn amount decreased from ¥4.8 billion to ¥4,575 million. - FY2021-Q3RestatedAnnual report
「Total lending commitment agreements ¥8,100 million ¥7,600 million Amount drawn ¥2,800 million ¥2,800 million Undrawn amount ¥5,300 million ¥4,800 million」
The status of the lending commitment agreements with the three relationship banks has been reaffirmed: total commitments of ¥7.6 billion, ¥2.8 billion drawn and ¥4.8 billion undrawn. - FY2021-Q2Decrease in commitment facilityAnnual report
「Total lending commitment agreements ¥8,100 million ¥7,600 million Amount drawn ¥2,800 million ¥2,800 million Undrawn amount ¥5,300 million ¥4,800 million」
For the lending commitment agreements with the three relationship banks, the total commitment decreased from ¥8.1 billion to ¥7.6 billion and the undrawn amount decreased from ¥5.3 billion to ¥4.8 billion, while the amount drawn remained unchanged at ¥2.8 billion. - FY2020RestatedAnnual report
「To secure and expand funding sources, the company will diversify its financing by obtaining the necessary funds through equity markets, bank loans, subsidies and other sources.」
The policy of diversifying funding by combining equity financing, bank loans, subsidies and other sources has been reaffirmed. - FY2020-Q3RestatedAnnual report
「In May 2019, the company issued new shares through an international offering and raised ¥7,097 million. The offering was conducted in anticipation of demand for SB623 sales in Japan, the United States and Europe, and the proceeds were scheduled to be used to diversify contract manufacturers and build SB623 inventory in order to increase mass-production capacity and establish a stable supply system.」
The ¥7,097 million raised through the international offering in May 2019 and the plan to use the proceeds to establish mass-production and stable supply systems have been reaffirmed. - FY2020-Q2AdvancedAnnual report
「To advance the businesses above, the company issued new shares through an international offering in May 2019 and raised ¥7,097 million. The offering was conducted in anticipation of demand for SB623 sales in Japan, the United States and Europe, and the proceeds were scheduled to be used to diversify contract manufacturers and build SB623 inventory in order to increase mass-production capacity and establish a stable supply system.」
The international offering of new shares was completed in May 2019, raising ¥7,097 million. The disclosed uses of proceeds included increasing mass-production capacity for SB623 for Japan, the United States and Europe, diversifying contract manufacturers and building inventory. - FY2020-Q1AdvancedAnnual report
「To advance the businesses above, the company issued new shares through an international offering in May 2019 and raised ¥7,097 million. The offering was conducted in anticipation of demand for SB623 sales in Japan, the United States and Europe, and the proceeds were scheduled to be used to diversify contract manufacturers and build SB623 inventory in order to increase mass-production capacity and establish a stable supply system.」
The company specified a plan to raise ¥7,097 million through an international offering of new shares and use the proceeds to establish mass-production and stable supply systems for SB623 in Japan, the United States and Europe. - FY2019AdvancedAnnual report
「During the fiscal year, the company issued the 13th Series of Stock Acquisition Rights through a third-party allotment, with an exercise-price adjustment clause, in March 2018 and raised ¥10,945 million. In addition, it entered into long-term commitment line agreements with Sumitomo Mitsui Banking Corporation and MUFG Bank, Ltd. for ¥1,000 million and ¥2,000 million, respectively, in November 2018, and with Mizuho Bank for ¥2,000 million in December 2018, securing funds for future growth investments.」
The company raised ¥10,945 million through exercises of the 13th Series of Stock Acquisition Rights and secured growth investment funding by entering into long-term commitment line agreements with three banks. - FY2019-Q3AdvancedAnnual report
「The company entered into the commitment line agreement below with Sumitomo Mitsui Banking Corporation to fund the establishment of post-launch manufacturing, logistics and sales systems for SB623.」
After the filing, the company entered into commitment line agreements totaling ¥5 billion with Sumitomo Mitsui Banking Corporation, MUFG Bank, Ltd. and Mizuho Bank to establish post-launch manufacturing, logistics and sales systems for SB623. - FY2019-Q2AdvancedAnnual report
「While the two programs above were progressing smoothly, in March 2018 the group issued the 13th Series of Stock Acquisition Rights through a third-party allotment, with an exercise-price adjustment clause, and completed all exercises in June of the same year, raising ¥11,058 million. The proceeds were scheduled to be used as growth funding for: 1) establishing post-launch manufacturing, logistics and sales systems for SB623; 2) research and development for the chronic-stage cerebral infarction program in Japan and for expanding territories ahead of future SB623 sales; and 3) research and development for expanding SB623 into new indications and introducing new compounds.」
All of the 13th Series of Stock Acquisition Rights were exercised in June 2018, raising ¥11,058 million. Specific uses of the proceeds included post-launch manufacturing, logistics and sales systems, development of the chronic-stage cerebral infarction program in Japan, territory and indication expansion, and the introduction of new compounds. - FY2019-Q1AdvancedAnnual report
「While the two programs above were progressing smoothly, in March 2018 the group issued the 13th Series of Stock Acquisition Rights through a third-party allotment, with an exercise-price adjustment clause, for estimated net proceeds of ¥15,290 million and an exercise period running through April 2021. The proceeds were scheduled to be used as growth funding for: 1) establishing post-launch manufacturing, logistics and sales systems for SB623; 2) research and development for the chronic-stage cerebral infarction program in Japan and for expanding territories ahead of future SB623 sales; and 3) research and development for expanding SB623 into new indications and introducing new compounds.」
The funding plan through the 13th Series of Stock Acquisition Rights was specified, including estimated net proceeds of ¥15,290 million, the exercise period, manufacturing, logistics and sales systems, development of the chronic-stage cerebral infarction program in Japan, and the expansion of territories and indications and introduction of new compounds. During the quarter, partial exercise also raised ¥3,390.2 million through the issuance of 1,200,000 shares. - FY2018AdvancedAnnual report
「Funds obtained from financing activities during the current consolidated fiscal year totaled ¥982 million, compared with ¥159 million in proceeds during the previous consolidated fiscal year. This mainly comprised proceeds of ¥1,650 million from long-term borrowings and ¥549 million in repayments of long-term borrowings.」
The company drew down ¥1,650 million in bank financing. In addition, after the filing, the company disclosed a plan to raise net proceeds of approximately ¥15,290 million through the 13th Series of Stock Acquisition Rights, with the funds to be used from April 2018 through January 2022. - FY2018-Q3AdvancedAnnual report
「At the end of the third quarter of the current consolidated fiscal year, fixed liabilities stood at ¥2,250 million, compared with ¥1,150 million at the end of the previous consolidated fiscal year, an increase of ¥1,100 million. This was attributable to a ¥1,100 million increase in long-term borrowings.」
In connection with the policy of diversifying funding sources, the company drew down bank financing during the quarter, with long-term borrowings increasing by ¥1,100 million. - FY2018-Q2AdvancedAnnual report
「The company entered into the commitment line agreement below with Mizuho Bank, Ltd. as reserve funding for the commercialization of the SB623 chronic traumatic brain injury program. 1. Borrowing limit: ¥1,600 million 5. Commitment period: 21 August 2017 to 31 July 2021」
The company entered into a commitment line agreement with Mizuho Bank, with a borrowing limit of ¥1.6 billion and a commitment period ending 31 July 2021, as reserve funding for the SB623 chronic traumatic brain injury program. - FY2018-Q1AdvancedAnnual report
「At the end of the first quarter of the current consolidated fiscal year, non-current liabilities stood at ¥2,283 million, compared with ¥1,150 million at the end of the previous consolidated fiscal year, an increase of ¥1,133 million. This was due to a ¥1,133 million increase in long-term borrowings.」
In connection with the policy of combining equity-market financing and bank loans, the company drew down bank financing during the quarter, with long-term borrowings increasing by ¥1,133 million. - FY2017First statedAnnual report
「To secure and expand funding sources, the company will diversify its financing by obtaining the necessary funds from the equity markets and through bank loans.」
The company has adopted a policy of diversifying funding by combining equity-market financing and bank loans to secure funds for research and development, indication expansion and sales-territory expansion. The filing also reports borrowings of ¥900 million and ¥250 million after the filing date.